Two-dose daclizumab induction in pediatric renal transplantation

Pediatric Transplantation

Volumn 13, Issue 4, 2009, Pages 490-494

  Jain, Amrish ^a,b   Valentini, Rudolph P ^b   Gruber, Scott A ^b   West, Miguel S ^b   Mattoo, Tej K ^b   Imam, Abubakr A ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute rejection; Daclizumab; Induction therapy; Pediatric renal transplantation

Indexed keywords

COTRIMOXAZOLE; CYTOMEGALOVIRUS ANTIBODY; DACLIZUMAB; GANCICLOVIR; MEPREDNISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ACUTE GRAFT REJECTION; ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; CADAVER DONOR; CHILD; CYTOMEGALOVIRUS INFECTION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRESCHOOL CHILD; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES;

EID: 65549097270     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2008.01033.x     Document Type: Article

References (21)

1. Vincenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998 : 338 : 161 165.
2. Garcia CD, Barros VR, Schneider L, et al. IL-2 antibody induction and the outcome of pediatric renal transplants. Transplant Proc 2002 : 34 : 2914 2915. (Pubitemid 35304964)
3. Meier-Kriesche HU, Palenkar SS, Friedman GS, et al. Efficacy of daclizumab in an African-American and Hispanic renal transplant population. Transpl Int 2000 : 13 : 142 145. (Pubitemid 30417370)
4. Di Filippo S. Anti-IL-2 receptor antibody vs. polyclonal anti-lymphocyte antibody as induction therapy in pediatric transplantation. Pediatr Transplant 2005 : 9 : 373 380. (Pubitemid 40780371)
5. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: Comparison between OKT3 and daclizumab. Transplantation 2005 : 80 : 477 481. (Pubitemid 41209415)
6. Swiatecka-Urban A. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: Current status. Paediatr Drugs 2003 : 5 : 699 716. (Pubitemid 37330566)
7. Wiland AM, Philosophe B. Daclizumab induction in solid organ transplantation. Expert Opin Biol Ther 2004 : 4 : 729 740. (Pubitemid 38667818)
8. Nashan B, Light S, Hardie IR, et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999 : 67 : 110 115.
9. Vincenti F, Nashan B, Light S. Daclizumab: Outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups. Transplant Proc 1998 : 30 : 2155 2158.
10. Vincenti F, Pace D, Birnbaum J, et al. Pharmacokinetic and Pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003 : 3 : 50 52. (Pubitemid 36306823)
11. Ter Meulen CG, Baan CC, Hene RJ, et al. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001 : 72 : 1709 1710. (Pubitemid 33096754)
12. Ekberg H, Persson NH, Kallen R, et al. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol 2003 : 58 : 670 677. (Pubitemid 37521943)
13. Osuna A, Gentil MA, Capdevila L, et al. Two doses of daclizumab with delayed introduction of low-dose tacrolimus in elderly recipients of cadaveric renal transplants from donors >55 years of age. Transplant Proc 2005 : 37 : 1438 1440. (Pubitemid 40712074)
14. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 1987 : 34 : 571 590. (Pubitemid 17080631)
15. North American Pediatric Renal Trials and Colloborative Studies (NAPRTCS). Annual Report. 2007 (available at https://web.emmes.com/study/ped/ annlrept/annlrept2007.pdf).
16. Niemeyer G, Koch M, Light S, et al. Long-term safety, tolerability and efficacy of daclizumab (Zenapax) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002 : 2 : 454 460. (Pubitemid 36306887)
17. Sellers MT, Mcguire BM, Haustein SV, et al. Two-dose daclizumab induction therapy in 209 liver transplants: A single-center analysis. Transplantation 2004 : 78 : 1212 1217. (Pubitemid 39426442)
18. Ortiz V, Almenar L, Martinez-Dolz L, et al. Induction therapy with daclizumab in heart transplantation - how many doses? Transplant Proc 2006 : 38 : 2541 2543.
19. Mastrobuoni S, Ubilla M, Cordero A, et al. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: Early experience. Transplant Proc 2007 : 39 : 2163 2166. (Pubitemid 47418179)
20. Stratta RJ, Alloway RR, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: Primary endpoint analysis of a multicenter, randomized study. Transplantation 2003 : 75 : 1260 1266. (Pubitemid 36513031)
21. Ji SM, Li LS, Cheng Z, et al. A single-dose daclizumab induction protocol in renal allograft recipients: A Chinese single center experience. Transplant Proc 2007 : 39 : 1396 1401. (Pubitemid 46907880)